Despite facing losses, Bio-Techne Corp TECH declared a dividend while some investors questioned its capital allocation strategy. The fourth quarter saw revenues surpassing estimates but also registered a dip in gross margin leading to a drop in stock. However, the organization remains positive and expects a 100 basis point margin expansion for FY26 following the divestiture of Exosome Diagnostics. This strategic shift aims at enhancing core operations and expanding the growth margin. In terms of partnerships, Bio-Techne initiated collaborations with Spear Bio and Kytopen to advance biomarker detection and expedite cell therapy manufacturing, respectively. In addition, the corporation announced a new $500M share repurchase program. Shifting focus on growth, Bio-Techne confronted academic pressures and funding cuts that contributed a drop in its stock prices. The FY22 report showed a rise in adjusted EPS. Lastly, Wells Fargo has begun a coverage with a price target of $59, proving mixed sentiments from the financial market.
Bio-Techne Corp TECH News Analytics from Thu, 19 Dec 2024 08:00:00 GMT to Fri, 08 Aug 2025 22:19:43 GMT - Rating 3 - Innovation 1 - Information 6 - Rumor -4
